Albert Bourla, Pfizer CEO (John Thys, Pool via AP Images)

Covid-19 roundup: Pfiz­er vac­cine's ef­fec­tive­ness de­clines faster than As­traZeneca, UK study finds; What about J&J boost­ers?

Two dos­es of Pfiz­er-BioN­Tech have greater ini­tial ef­fec­tive­ness against new Covid-19 in­fec­tions, but this ef­fec­tive­ness de­clines faster than two dos­es of Ox­ford-As­traZeneca, ac­cord­ing to a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.